Premium
Allogeneic Bone Marrow Transplantation in Childhood Leukemia
Author(s) -
Kato Shunichi,
Yabe Miharu,
Yabe Hiromasa,
Kubota Chidori,
Hinohara Tomoyuki,
Hattori Kinya,
Shinohara Osamu
Publication year - 1991
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1991.tb02584.x
Subject(s) - medicine , subclinical infection , leukemia , myeloid leukemia , bone marrow , acute leukemia , bone marrow transplantation , transplantation , gastroenterology
Allogeneic bone marrow transplantation was performed in 94 patients with hematologic malignancies or other various diseases during the period between March 1982 and November 1990 at Tokai University Hospital. Projected disease‐free survival rates of HLA genotypically identical marrow recipients were 88.9% for chronic myeloid leukemia transplanted in the first chronic phase (N = 9), 90.9% for acute leukemia in the first complete remission (N = 15), 54.5% for acute leukemia in later remissions (N = 14), 62.5% for solid tumors (N = 8) and 0% for patients transplanted in relapse (N = 7). The rate for HI A‐mismatched marrow recipients with leukemia was 27.8% (N = 16). For patients with non‐neoplastic diseases it was 100% regardless of HLA‐compatibility (N = 26). The quality of life in long‐term surviving pediatric marrow recipients has been acceptable. Common abnormalities among survivors are long‐lasting hypogonadism due to radiation and subclinical impairment of lung function in the first year post‐BMT. About two‐thirds of children experienced a transient decrease in growth velocity in the immediate posttransplant period.